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significantly reduced by using the ETHICON SECURESTRAP™ Open fixation device 
compared with suture fixation of IPOM mesh. This shows promise of reducing open 
IPOM procedure time which may realize related patient benefits of reduced anesthe-
sia time, infection risks, costs etc. Also, reduction in surgical stress could potentially 
offer improvement in surgical performance – benefiting the surgeon, the patient 
and the health care system.
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Objectives: A pilot care managing programme was introduced in Hungary in 1999. 
The conceptual foundations of the Hungarian implementation of managed care is 
closer to what was called the GP fundholding in the UK than HMOs in the USA. The 
purpose of the study is to analyse the cost savings realized within the Hungarian 
care managing programme. MethOds: The data derive from the financial data-
base of the Hungarian National Health Insurance Fund Administration (NHIFA) 
covering the period 1999-2007. We identified the annual cost savings realized by 
the Care Managing Organizations. The Hungarian CMOs was financed through 
a risk adjusted capitation fee and the health services covered by CMOs were 
defined in legal regulations. Cost saving was defined as the difference between 
the annual revenues (capitation fee) and expenditures (real utilization) of care 
managing organizations. Results: During the study period the total number of 
persons covered by the care managing programme increased from 1.5 % of the 
Hungarian population to its peak of 19.4 % in 2005. The cost saving of the care 
managing programme was 63138000 Hungarian Forint (HUF) or 249756 Euro (EUR) 
in 1999; 457662600 HUF (1759945 EUR) in 2000, 1109442300 HUF (4322246 EUR) in 
2001; 2710926900 HUF (11157503 EUR) in 2002; 1452041100 HUF (5727683 EUR) in 
2003, 3799000306 HUF (15094804 EUR) in 2004; 3709400000 HUF (14954510 EUR) in 
2005; 4964600000 HUF (18786048 EUR) in 2006 and 3669000000 HUF (14599437 EUR) 
in 2007. These amounts resulted in the following annual savings rate: 1999: 3.6%; 
2000: 10.4%; 2001: 6.5%; 2002: 8.7%; 2003: 3.4%; 2004: 4.0%; 2005: 2.1%; 2006: 2.9% and 
2007: 2.9%. cOnclusiOns: With the development of the Hungarian care managing 
system, the average number of enrolees increased. Cost savings of Care Managing 
Organizations varied between 2.1-4.0 % during the mature period of this programme.
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Objectives: To systematically review and synthesize published evidence on the 
impact of pharmaceutical price controls, such as price cuts, price caps, price freezes 
or international price referencing. MethOds: A literature search was conducted 
in Medline, Scopus, Econlit, Web of Science and ABI/INFORM to identify relevant 
studies published in English to March 2013. Results: Forty-seven out of 3787 initial 
studies were included. Price caps and price reductions were most commonly studied 
in the literature, followed by reference pricing and price freezes. The evidence indi-
cates that price controls reduce company profits and have a detrimental effect on 
pharmaceutical research and development, pipeline productivity and investment. 
They may also inhibit, reduce or delay new product launches, increase parallel 
exports and diminish availability of generics due to disincentives and, hence, may 
reduce product availability, increase withdrawals and shortages. In terms of public 
expenditure about half of the studies indicate realized savings, but the other half 
indicate no effect or even increases in expenditure. In terms of effects on patients, 
studies indicate in the short term welfare gains due to lower cost and better access, 
but also losses due to drug shortages and availability issues. Long-term effects 
appear to be welfare losses due to reductions of discoveries, resulting from the 
disinvestment associated with the lower revenues. cOnclusiOns: Effects of price 
controls are ambiguous in the case of pharmaceuticals. Price controls reduce drug 
acquisition cost and increase access in the short run. On the other hand, they may 
decrease patient welfare and access as they can cause product shortages, withdraw-
als and launch delays. Moreover, they may reduce the likelihood for new product dis-
coveries. Contrary to common beliefs, price controls not always reduce expenditure. 
Thus careful consideration is needed in designing drug price policies. Value based 
pricing approaches may be more effective alternatives compared to price cutting.
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Objectives: Relationships between National/Regional Health care Systems (NHS) 
and pharmaceutical companies can and should be based on a cooperative venture, 
built on the expertise of each side, that best meets clearly defined public needs 
through the appropiate allocation of resources, risks and rewards, while preserv-
ing transparency and its independence. However, joint working can be difficult to 
initiate due to the number of parties involved and the lack of clear shared objec-
tives. Guidelines can be very useful to support the NHS/Pharmaceutical Partner’s 
commitment. To our knowledge, there are no such published guidelines in Spain. 
This first guidance in Spain was designed with the main aim of identifying and 
simplifying the initiation, the start-up phase and the remainder of joint working 
projects between the Catalan Heath System (CatSalut) and pharmaceutical com-
panies. MethOds: A flowchart was designed to describe the standard steps and 
timelines suggested to start, implement, monitor and evaluate a Joint Working pro-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. MethOds: To understand trends in use of health economic information 
we conducted targeted search for clinical guidelines, expert recommendations, and 
consensus statements with specific mention of “cost” or “economic” or related terms. 
A systematic literature search was undertaken for the databases Pubmed, Google 
Scholar and Cochrane. The guidelines published between 2003-2012 were included. 
For guidelines which met the search criteria, data was collected for the name of the 
authors, indication, year of publication, country/region, and context of use of cost/eco-
nomic evidence. Results: Sixteen clinical guidelines published between 2003-2012 
met the inclusion criteria for specific mention of cost/economic evidence. More than 
50% of these guidelines were published between 2006-2012. For indication, 3 out of 
16 guidelines were for diabetes, while the rest were for different indications. In these 
16 guidelines “cost effectiveness” was mentioned 14 times, either referencing cost-
effectiveness data or to mention the importance of such data for selecting treatment 
options. The guidelines commonly cite high cost of disease or high economic burden 
as one of the considerations for developing new recommendations (11 out of 16). 
Another term that was commonly used by these guidelines was “cost-benefit,” which 
was mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 
out of 16 times) in these guidelines. cOnclusiOns: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations.
PHP195
reasons given By tHe eUroPean MediCines agenCy for revising 
disease-sPeCifiC sCientifiC gUidelines
Caron M., Acquadro C.
Mapi Research Trust, Lyon, France
Objectives: To review all the reasons provided by the European Medicines Agency 
(EMA) to substantiate the need for revisions to or updates of disease-specific scien-
tific guidelines developed by the Committee for Medicinal Products for Human Use 
(CHMP). MethOds: All the scientific guidelines issued by the CHMP were reviewed 
on the EMA’s website. The guidelines not focusing on disease-specific issues were 
not selected, i.e., guidelines listed in the following sections: Clinical Pharmacology 
and pharmacokinetics, General, Herbal Medicinal products, Information on medici-
nal products, and Radiopharmaceutical and diagnostic agents. Results: A total of 
182 disease-specific scientific guidelines were reviewed. The review identified 21 
concept papers developed with the intent of revision (11.5% of specific guidelines). 
The analysis of the concept papers revealed that four main reasons were claimed: 
1) Clarifications needed for pediatric development [10 concept papers: acute heart 
failure, asthma, Crohn’s disease, hepatitis C, hypertension, glucocorticoid-induced 
osteoporosis, irritable bowel syndrome (IBS), multiple sclerosis, pain, and ulcerative 
colitis); 2) Evolution in the field and treatments (n= 9); 3) Clarifications on endpoints 
identification and measurement (n= 7); and 4) Safety aspects (n= 6). For instance, 
in asthma, one of the critical aspects to be discussed regarding endpoints was “the 
need to reinforce the use of clinical measurements (symptoms) and patient-reported outcome 
measures to complement lung-function parameters.” In IBS, regulators asked that “An 
evaluation whether more clear recommendations as regards the use of certain 
scales or newly developed PROs can be made is also desirable.” cOnclusiOns: The 
main reason for the EMA to revise disease-specific guidelines is the need for provid-
ing guidance in pediatric issues. This is in line with the introduction of Pediatric 
Investigation Plans (PIPs) by the European Commission in January 2007 to help 
ensure that medicines for children are included in the mainstream drug develop-
ment process in Europe.
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Objectives: This study compared fixation time using ETHICON SECURESTRAP™ 
Open device to suture fixation of IPOM mesh in ventral/ incisional hernia repair. It 
also assesses surgeon-reported levels of task load experienced during the two fixa-
tion approaches. MethOds: Nine surgeons inserted skirted mesh using IPOM tech-
nique on created incisional defects in live swine models. Each surgeon performed 
two suture (using their standard technique) and two ETHICON SECURESTRAP™ 
Open fixation procedures. The duration of fixation procedure starting from mesh 
preparation through the last firing or suture knot was recorded. Surgical work-
load was measured using the validated Surgery Task Load Index (SURG-TLX) 
questionnaire. Time savings and task load reduction were determined by the 
lower limit of the two-sided 95% confidence interval for the difference between 
suture fixation and ETHICON SECURESTRAP™ Open groups. Results: A total of 
38 IPOM fixation procedures were performed with equal numbers using suture 
and ETHICON SECURESTRAP™ Open. 89% reduction in mean fixation time was 
observed from suture to mechanical fixation with ETHICON SECURESTRAP™ Open 
[mean reduction: 34.9 minutes (SD: 17.9 minutes); p< 0.0001]. Similarly, 55% reduc-
tion in perceived overall workload was observed with SECURESTRAP™ Open com-
pared to suture fixation [mean reduction: 22.17 (SD: 15.12); p= 0.0003]. ETHICON 
SECURESTRAP™ Open demonstrated significantly lower ratings in five of the six ele-
ments of surgical task load, namely – Mental Demand, Physical Demand, Situational 
Stress, Task Complexity, and Temporal Demand [p< 0.05 for all] compared to suture 
fixation. cOnclusiOns: Time for fixation and related surgical task load can be 
